June 10, 2020 / 12:46 PM / a month ago

BRIEF-Catalyst Biosciences Completes Marzaa Pharmacokinetic & Pharmacodynamic Study

June 10 (Reuters) - Catalyst Biosciences Inc:

* CATALYST BIOSCIENCES COMPLETES MARZAA PHARMACOKINETIC & PHARMACODYNAMIC STUDY

* CATALYST BIOSCIENCES - PHASE 1 MAA-102 STUDY RESULTS SUPPORT USE OF SQ MARZAA TO TREAT EPISODIC BLEEDING

* CATALYST BIOSCIENCES - ON TRACK TO ENROLL FIRST PATIENT IN ITS PHASE 3 REGISTRATION TRIAL EVALUATING EFFICACY OF SQ MARZAA IN 2020 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below